2,5-Dimethoxy-4-trifluoromethylamphetamine

2,5-Dimethoxy-4-trifluoromethylamphetamine (DOTFM) is a psychedelic drug of the phenethylamine and amphetamine chemical classes. It was first synthesized in 1994 by a team at Purdue University led by David E. Nichols.[1] DOTFM is the alpha-methylated analogue of 2C-TFM, and is around twice as potent in animal studies. It acts as an agonist at the 5HT2A and 5HT2C receptors.[1] In drug-substitution experiments in rats, DOTFM fully substituted for LSD and was slightly more potent than DOI.[1]

2,5-Dimethoxy-4-trifluoromethylamphetamine
Clinical data
Other names2,5-Dimethoxy-4-trifluoromethylamphetamine
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H16F3NO2
Molar mass263.26 g/mol g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

See also

  • DOx

References

  1. Nichols DE, Frescas S, Marona-Lewicka D, Huang X, Roth BL, Gudelsky GA, Nash JF (1994). "1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist". Journal of Medicinal Chemistry. 37 (25): 4346–4351. doi:10.1021/jm00051a011. PMID 7996545.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.